Researchers develop way to expand regulatory T-cells to help prevent GVHD.
Researchers have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent graft-versus-host disease (GVHD), a serious risk in stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system.
"Tregs play a dominant role in transplantation tolerance," said Claudio Anasetti, M.D., corresponding author of a study carried out by a team of Moffitt Cancer Center investigators. "Adoptive transfer of freshly isolated human Tregs has prevented GVHD in patients treated with allogeneic (other than self-donated) stem cell transplants. However, some transplants will require a greater number of Tregs that can only be obtained through expanding Tregs outside of the body."
The researchers suggest that therapeutic applications will require Tregs to be expanded by more than a hundredfold.
"There is a need to improve on Treg expansion protocols before allo-specific Tregs can be brought into the clinic," said Anasetti, chairman of the blood and marrow transplant department at Moffitt.
The authors noted that a recently adopted expansion process has used dendritic cells to activate Tregs.
"Dendritic cells have been identified as having unique capabilities for expanding Tregs," said Anasetti, whose work focuses on preventing GVHD in mouse models and in humans.
To carry out the present study, Anasetti and his fellow researchers adopted a one-step process to expand allo-specific Tregs by dendritic cell stimulation.
"Our work opens an opportunity to study tissues as sources of antigens for indirect presentation to activate and expand therapeutic Tregs," Anasetti said. "If effective, this approach could prevent GVHD while sparing, at least in part, graft-versus-leukemia or graft-versus-tumor responses."
Citation: "Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly;" A. Veerapathran, C. Anasetti, et al.; Blood, 2011; DOI: 10.1182/blood-2011-02-337097
Abstract: http://dx.doi.Org/10.l 182/blood-2011-02-337097 Contact: Claudio Anasetti, firstname.lastname@example.org
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Advanced Stem Cell Technology|
|Publication:||Stem Cell Lab World|
|Date:||Nov 21, 2011|
|Previous Article:||Scientists reprogram stem cells to improve transplant effectiveness.|
|Next Article:||Fluxion Biosciences launches the F1 giga-ohm seal plates for the Ionflux System.|